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Abstract
Background: Pelargonium sidoides is an important traditional medicine in South Africa with a well-defined history
of both traditional and documented use of an aqueous-ethanolic formulation of the roots of P. sidoides (EPs 7630),
which is successfully employed for the treatment of respiratory tract infections. There is also historical evidence of
use in the treatment of tuberculosis. The aim of this study was to develop a platform of Mycobacterium tuberculosis
(Mtb) kinase enzymes that may be used for the identification of therapeutically relevant ethnobotanical extracts
that will allow drug target identification, as well as the subsequent isolation of the active compounds.
Results: Mtb kinases, Nucleoside diphosphokinase, Homoserine kinase, Acetate kinase, Glycerol kinase, Thiamine
monophosphate kinase, Ribokinase, Aspartokinase and Shikimate kinase were cloned, produced in Escherichia coli and
characterized. HPLC-based assays were used to determine the enzyme activities and subsequently the inhibitory
potentials of varying concentrations of a P. sidoides extract against the produced enzymes. The enzyme activity assays
indicated that these enzymes were active at low ATP concentrations. The 50% inhibitory concentration (IC50) of an
aqueous root extract of P. sidoides against the kinases indicated SK has an IC50 of 1.2 μg/ml and GK 1.4 μg/ml. These
enzyme targets were further assessed for compound identification from the P. sidoides literature.
Conclusion: This study suggests P. sidoides is potentially a source of anti-tubercular compounds and the Mtb kinase
platform has significant potential as a tool for the subsequent screening of P. sidoides extracts and plant extracts in
general, for compound identification and elaboration by selected extract target inhibitor profiling.
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Background
The prevalence in tuberculosis (TB), together with the re-
cent increase in the incidence of multidrug-resistance
(MDR) cases, has led to the search for new drug targets
and new drugs that are effective against Mtb. TB is often a
fatal disease, and one that poses a global threat to human
health [5, 6]. Globally, infection associated with TB is sec-
ond only to HIV/AIDS as the greatest killer due to a single
initiating infectious agent [25]. Out of the 9 million people
infected with TB in a year, 3 million are left untreated,
acting as a reservoir for further infection. Many of these 3
million untreated cases live in poverty with minimal
access to healthcare. Over 95% of TB cases and deaths are
in developing countries such as South Africa, often where
the percentage of HIV/AIDS co-infection is high, and
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therefore occurs in individuals with compromised
immune systems (WHO, 2020) [25].
TB is caused by various strains of Mycobacterium tuber-
culosis, commonly affects the lungs, and is transferrable
from person to person through the air. Mtb is an intra-
cellular parasite normally residing in the human macro-
phages, where its survival and growth depends on com-
plex networks of the attenuation of macrophage activity
by the Mtb bacilli. Mtb has not only developed a number
of mechanisms to evade onslaught from such host macro-
phage immune responses as reactive oxygen and nitrogen
species, but it has also evolved a metabolism that has
allowed it to survive in this very specialized niche environ-
ment [27]. It has become evident that one of the mecha-
nisms to arrest the progression of Mtb into full-blown
infection is a multi-targeted approach [23]. The key ques-
tion which arises is, “Can a single plant extract be used to
screen multiple targets as a means of identifying novel
synergistic anti-infective properties?” Medicinal plants
have been used for the treatment of several diseases and
the plant extract identified for analysis was that from Pel-
argonium sidoides, as this plant has a 200 year docu-
mented history of ethnobotanical use in the treatment of
tuberculosis and other infections [1, 2, 12, 13, 15, 18, 20].
This includes well documented reports in literatures that
suggest the medicinal properties and efficacy of P. sidoides
against M. tuberculosis and other bacterial infections [16,
9, 17, 22]. The mechanisms and targets of this anti-
tubercular activity are, however, not defined. The
aqueous-ethanolic extract of P. sidoides (EP® 7630) roots
have been used to treat bacterial infections, as well as to
induce the production of the pro-inflammatory cytokines
TNF-α and IL-6 in human blood human immune cells, al-
leviating symptoms associated with acute bronchitis [12,
13]. This extract is licensed in Germany as herbal medi-
cine for the treatment of upper respiratory tract infections
[26].
This investigation was therefore set up to target a func-
tionally diverse range of Mtb kinase enzymes as a mechan-
ism of identifying potential Mtb drug targets using the
complexity found in medicinal plant extracts as the source
of chemical diversity. It was also decided to select a range
of Mtb kinases which, where possible, do not occur within
mammalian biochemistry. Kinases have been classified into
25 families of homologous proteins, with the families as-
sembled into 12 fold-groups based on the similarity of their
structural folds [3, 4]. It has further been demonstrated that
each of the 12 fold-groups has a distinct phosphoryl trans-
fer mechanism [11], and it was therefore decided to select
the kinase enzyme targets from 6 of the 12 fold-groups,
thereby representing 6 distinct phosphoryl transfer mecha-
nisms. The six identified phosphoryl transfer mechanisms
all have distinct ATP binding motifs. The selection of these
kinases should therefore identify different classes’
compounds capable of binding ATP. The enzymes selected
are crucial for the metabolism and survival of Mtb. As rela-
tively large number of enzymes was to be comparatively
simultaneously assessed it was envisaged to keep the en-
zyme purification and assays as simple as possible.
The eight specific Mtb kinases targeted are Nucleo-
side diphosphokinase (NDK, EC 2.7.4.6), Homoserine
kinase (HSK, EC 2.7.1.39), Acetate kinase (AK, EC
2.7.2.1), Glycerol kinase (GK, EC 2.7.1.30), Thiamine
monophosphate kinase (ThiL, EC 2.7.4.1), Ribokinase
(RBKS, EC 2.7.1.15), Aspartokinase (AsK, EC 2.7.2.4),
and Shikimate kinase (SK, EC 2.7.1.71) [7, 10, 14, 21].
The kinases were expressed in Escherichia coli, puri-
fied and the activity determined through HPLC-based
assays. The inhibitory properties of a P. sidoides
extract were then investigated against the character-
ized kinases.
Results
The enzymes were expressed in E. coli with His-tags to
facilitate the purification of these enzymes, and their
functionality was validated by determining their enzyme
activity before carrying out the P. sidoides inhibitory
experiments.
Cloning, expression and purification of enzymes
The Mtb kinase genes were PCR-amplified from M.
tuberculosis H37Rv genomic DNA, yielding amplicons
of 415, 952, 1162, 1558, 1006, 919, 1268 and 520 bp
for ndkA (nucleoside diphosphate kinase), ThrB
(homoserine kinase), ackA (acetate kinase), glpK (gly-
cerol kinase), thil (thiamine monophosphate kinase),
rbks (ribokinase), ask alpha and ask beta (aspartoki-
nase) and aroK gene (shikimate kinase), respectively.
These were subcloned into the selected plasmids and
confirmed via sequencing.
All enzymes were expressed in E. coli BL21 (DE3) sub-
sequent to IPTG induction. Following nickel-affinity
purification using either native or denaturing means, the
proteins was verified by SDS-PAGE as outlined in Fig. 1
and in Additional file 1 for the detailed break-down of
the fractions obtained. Acetate kinase (AK) and glycerol
kinase (GK) were both well expressed however the final
eluate yielded lower levels of protein. They were both
however still used in the screening as sufficiently high
levels of enzyme activity were obtained. It was decided
to keep these enzymes in the screen panel as one of the
primary aims of setting up the screen panel was to assess
if the panel may be used to identify compound target se-
lectivity from mixtures such as plant extracts. It is envis-
aged that a higher fidelity secondary screen will be set
up, using purer enzyme, once the target has been identi-
fied. The secondary screen will be used for compound
identification.
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Enzyme activity assays
The effect of the ATP concentration on the steady state
specific activity of the M. tuberculosis kinases was expressed
over a concentration gradient of ATP (Fig. 2). As the en-
zymes were recombinantly expressed in E. coli, the specific
activity of the individual enzymes referred to throughout
the document is the recombinant specific activity as the en-
zymes were not obtained from their native host. The best-
fit to the data was obtained for the specified kinetic model
using the non-linear regression algorithms as outlined using
the GraphPad Prism® 5 software. The variation in the max-
imum specific enzyme activity for each enzyme was vast,
ranging from approximately 0.14 nM/minute/nM protein
for AsK to in excess of 3000 nM/minute/nM protein for
SK, indicative of the great variation in binding affinity for
ATP of the selected enzymes.
P. sidoides inhibitory assay
The inhibitory activities of various dilutions of P. sidoides
extracts were concentration-dependent in all the kinases
except HSK, RBKS and AsK (Fig. 3). No inhibition was ob-
served at 1 × 10− 6 mg/ml of P. sidoides on ThiL and RBKS
kinases. The most susceptible enzymes to P. sidoides ex-
tract were SK and GK with the lowest IC50 values of 1.17
Fig. 1 SDS-PAGE gels of the Mtb his-tagged kinases purified from E. coli BL21 (DE3). M represents the molecular mass marker (PageRuler™ Plus
Pre-stained Protein Ladder, Thermo Scientific, USA) with the sizes of the bands indicated to the left of the gels in kDa. a NDK, 14,4 kDa. b HSK,
33.4 kDa. c AK, 43.7 kDa. d GK, 58.2 kDa. e ThiL, 36.4 kDa. f RBKS, 32.3 kDa. g AsK alpha, 44.6 kDa and AsK beta, 18 kDa. h SK, 20.7 kDa
Fig. 2 The effect of the ATP concentration on the specific enzyme activities of the purified kinase enzymes
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mg/ml and 1.4 mg/ml, respectively, when compared to
other kinases (Table 1).
The validation for presence of the enzymes to comple-
ment the enzyme functionality data was demonstrated
using peptide mass spectroscopy (Table 2). The data and
the diagnostic mass fragmentation patterns for selected
peptides are outlined in Additional file 1.
Discussion
A range of kinases was selected for screening, based on
representing some of the 12 fold-groups that have distinct
phosphoryl transfer mechanisms, with a total of 6 distinct
phosphoryl transfer mechanisms represented in the 8 en-
zymes used in this study [11]. The purification of the pro-
teins was challenging, but a variety of different techniques
were investigated in order to acquire sufficient amounts of
relatively pure protein (as estimated by PAGE) to run all
assays simultaneously as part of a preliminary medicinal
plant extract screen. The presence of each kinase was
demonstrated by enzyme activity, SDS-PAGE and/or MS
analysis. The competitive inhibition of the kinase reaction
may manifest either as inhibiting the binding of ATP or by
the inhibition of the binding of the enzyme substrate that
is to be phosphorylated. As these enzymes were selected
based on the fact that they all have distinct phosphoryl
transfer reactions as well as distinct substrates, it was en-
visaged that the plant extract may demonstrate a signifi-
cant variation on the IC50s obtained. This was found to be
the case, with SK and GK having IC50 values of 1.17mg/
ml and 1.4mg/ml, respectively, with all the other enzymes
having IC50s of at least one order of magnitude higher.
Clearly, the kinases selected could be used in a primary se-
lection to identify targets for a plant extract. The selected
enzymes could then be used in a more stringent secondary
screen to identify the active compounds. What is signifi-
cant is one of the major active ingredients of P. sidoides is
gallic acid, which is a shikimic acid mimic (the substrate of
SK) (Fig. 4). Gallic acid and a range of O-galloylated
compounds have been demonstrated to be present in the
extracts of P. sidoides [12]. SK has been identified as being
a potential target to develop antimicrobial agents for Mtb
[8, 19]. An associated species of Pelargonium used in
South Africa for medicinal purposes is Pelargonium reni-
forme. P. reniforme produces O-galloylated glycerol (gly-
cerol-1-gallate) which could be a potential bi-functional
inhibitor of both SK and GK. If only low levels of glycerol-
1-gallate are synthesized in P. sidoides, however if the
binding constants of glycerol-1-gallate for SK and GK is
high enough inhibition will still occur and probably syner-
gistically. As the enzymes selected are all kinase enzymes it
Fig. 3 The inhibitory activities of P. sidoides against the purified kinases
Table 1 Kinases and their respective IC50 values derived from
the dose-response curves
Kinase IC50 value (mg/ml)
NDK 9.28
HSK 13.72
AK 212.3
GK 1.40
ThiL 16.01
RBKS 73.42
AsK 31.16
SK 1.17
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Table 2 Kinases and their respective MS validation
Kinase Peptide Probability (%) Unique Peptides Unique Spectra
NDK (R)KGLTIAALQLR(T) 100 11 18
HSK (K)GFAVTELTVGEAVR(W) 100 65 100
AK (K)MLAEDGIDLQTcGLVAVGHR 99.7 34 47
GK (R)DQLGIISGAAQSEALAR(Q) 99.7 55 68
ThiL (R)TVVSTDMLVQDSHFR(L) 100 3 3
RBKS ND
AsK (R)cVEYARRHnIP(V) 99.7 3 3
SK ND
ND not detected
Fig. 4 Structural similarity between gallic acid and a few o-galloyl derivatives which are components of P. sidoides and shikimic acid, the
substrate to SK
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is realistic to believe that one of the binding mechanisms
is in the kinase ATP binding site. These results clearly
demonstrate that this platform of Mtb kinase enzymes can
be used as a primary selection strategy for the identifica-
tion of active ingredients in plant extracts that allows for
the stratification of the inhibition of Mtb kinase enzymes
and the validation of the extracts potential medicinal
properties.
The traditional use of the plant root of P. sidoides was for
a wide range of ailments including tuberculosis (for well
researched review on the ethnobotanical and medicinal use
of P. sidoides and other Pelargonium specices see reference
[2];). P. sidoides forms the basis of Charles Henry Stevens
secret cure for tuberculosis, “Stevens Cure” and was called
“Umckaloabo”. Modern aqueous-ethanolic formulation of
the roots of P. sidoides (EP® 7630) has been successfully
employed for the treatment of ear, nose and throat disor-
ders as well as respiratory tract infections [12, 13].
The data exhibited only moderate direct antibacterial
capabilities against a spectrum of Gram-positive and
Gram-negative bacteria, although convincing data was
provided in support for the improvement of immune func-
tions at various levels, hence, validating the medicinal uses
of EP® 7630. The concentrations and nature of the active
compounds in the extract are unknown. This data how-
ever, provided support to validate the medicinal use of P.
sidoides. However, the remedial effects are not yet associ-
ated with mechanistic structure and function analyses and
therefore further investigations are required in order to
study the functional relationships between the O-galloly-
lated compounds and SK and GK. Phytochemical studies
show the presence of a large number of other secondary
metabolites in the plant, such as tannins, coumarins, phen-
olic acids, phenylpropanoid derivatives and other chemical
constituents [12, 17]. This identified platform of Mtb ki-
nases could serve as a screen to allow for mechanistic
studies to be carried out on ethnobotanical plant extracts.
The traditional use of P. sidoides and the present enzyme
results indicate the potential use of this kinase platform to
directly relate traditional use to target mechanistic investi-
gations thereby identifying the potential drug target. These
data should eventually contribute to evidence-based trad-
itional medicines.
Conclusions
In conclusion, selected Mtb kinases were successfully
expressed in E. coli and purified and validated by SDS-
PAGE, enzyme activity and/or MS spectroscopy. The en-
zyme functionality was validated through the enzyme ac-
tivity of the purified proteins, and the effect of a P. sidoides
plant extract on their activities was determined. The most
susceptible enzymes tested were SK and GK, with the low-
est IC50 values. This suggests that both SK and GK could
be used as targets through which P. sidoides extracts could
be characterized in terms of the specific chemistry of the
inhibitors. As these two enzymes have different phosphoryl
transfer mechanisms is it probable that different classes of
compounds will be selected. The biosynthesis of the aro-
matic amino acids occurs via chorismate, the precursor to
which is shikimate. As mammals do not have the bio-
chemistry for the synthesis of chorismate or any of its
intermediates, SK is a good validated target for Mtb.
The human essential amino acids, tyrosine, tryptophan
and phenylalanine are all synthesized using chorismate
as the precursor. P. sidoides contains a broad range of
O-galloylated compounds all of which are potential in-
hibitors of SK and in the case of glycerol-1-gallate, GK.
Having identified the potential targets for P. sidoides in-
hibition SK and GK will therefore serve as a good
screen for compound identification and validation from
P. sidoides extracts.
Methods
Materials
H37Rv genomic DNA was received from Professor Ian
Wiid, University of Stellenbosch, South Africa. The Mtb
aroK gene (encoding Shikimate Kinase) in pET15-b was
received from the laboratory of Chris Abell, University of
Cambridge. All other genes were cloned in-house as out-
lined in section 5.3. All PCR reagents were from Kapa Bio-
systems (KAPA HiFi for gene amplification and KAPA 2G
Fast for screening), and cloning materials were purchased
from Epicentre Technologies, USA (Fast-Link™ DNA
Ligation Kit) or Zymo Research, USA (Zyppy™ Plasmid
Miniprep kit and Zymoclean™ Gel DNA Recovery Kit). Ol-
igonucleotides for gene amplification were obtained from
IDT Inc. (USA). All other chemicals used were at least
analytical grade and were obtained from Sigma-Aldrich.
Plant material
The P. sidoides fresh plant material was supplied by the
Natural Plants and Agroprocessing (NPA) division of
CSIR Biosciences through the CSIR Enterprise Creation
for Development (ECD) division, Pretoria, South Africa.
In an endeavor to limit the environmental destruction due
to the uncontrolled wild harvesting of plants the ECD of
the CSIR has facilitated the cultivation of a number of im-
portant ethnobotanical plants of known high usage, P.
sidoides being one of them. The plants used were culti-
vated by Rodene Nursery, (ECD Sample number, ECD-
MP-0252; Extract number, PEL-223-48448A). All plant
taxonomy at the ECD was done in conjunction with South
African National Biodiversity Institute (SANBI) which
forms part of the The Plant List protocol.
The primary pre-processing post agricultural harvest-
ing involved washing of the biomass (stalks and leaves
cut into smaller pieces) prior to drying at 40-50 °C, over
3–5 days. The material was then milled using a hammer
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mill before carrying out the batch extraction process.
The extraction was carried out in a glass jacketed perco-
lation column. The biomass material was held in place
within the column using mutton cloth. The percolation
process was then carried out over 7 h. The extraction
solvent used was ethanol (43% v/v EtOH, 1.25 L) and ef-
fective dried raw material loading (0.25 kg). The solvent
was re-circulated through the column reactor over the
period of 7 h. The solvent is pumped in at the top of the
percolation column and allowed to diffuse through the
column under gravitational force. The flow rate was esti-
mated to be 36ml/min. The percolator column dimen-
sions (out diameter 11 cm, column length ~ 32 cm). The
recovered filtrate (ex. percolation) was then collected and
ethanol removed using a Buchi evaporator (40-60 °C, − 85
kPa over 1–2 h). The extract yield was 16.917 g (yield
6.76% m/m). The crude extract was stored at 4 °C.
Cloning of the kinase genes from M. tuberculosis
The genes that were cloned were ndka (nucleoside diphos-
phate kinase NDK; Rv2445c), thrB (homoserine kinase
HSK; Rv1296), ackA (acetate kinase AK; Rv0409), glpK (gly-
cerol kinase GK; Rv3696c), thiL (thiamine monophosphate
kinase Thil; Rv2977c), rbks (ribokinase RBKS; Rv2436) and
ask (aspartokinase AsK; Rv3709c). The aroK gene (encod-
ing Shikimate Kinase) was obtained from the laboratory of
Chris Abell, University of Cambridge. The genes were amp-
lified from H37Rv genomic DNA using the oligonucleotide
primers shown in Table 3, and the PCR products subcloned
into the selected pET vector (Novagen, Germany) using the
applicable restriction enzymes.
Expression of Mtb kinases
E. coli BL21(DE3) (Novagen, USA) was used as produc-
tion host. For AsK production, two co-transformed plas-
mids were used for co-expression of the alpha and beta
monomers. The recombinant strains were cultivated in
250 ml LB broth supplemented with the appropriate an-
tibiotic(s) at 37 °C with shaking at 200 rpm and, at
OD600 ~ 0.6, induced with 1 mM Isopropyl β-D-1-thio-
galactopyranoside (IPTG) and incubated overnight at
28 °C. Production of SK was carried as described by Ken-
yon et al. [10]. The cells were harvested by centrifuga-
tion at 4080 g for 10 min at 4 °C.
Purification of Mtb kinases
The biomass pellets were resuspended in 20ml Binding
Buffer (1M NaCl, 20 mM Tris-HCl and 5mM Imid-
azole: pH 7.9), lysed by sonication and re-centrifuged to
separate the soluble and insoluble fractions.
The soluble kinases NDK, ThiL, RBKS, AsK and SK
were purified using the Profinia™ Affinity Chromatography
Protein Purification System (Bio-Rad, USA) with a 1ml
column containing nickel-iminodiacetic acid (Ni-IDA)
resin. The Standard Native conditions and protocols were
followed according to the manufacturer’s instructions. For
AK and GK, MagReSyn™ NTA (ReSyn™ Biosciences. South
Africa) was used for purification. The manufacturer’s
scaled-up protocol was followed. The eluates were dia-
lysed overnight in each selected dialysis buffer (Table 4).
HSK was insoluble and was purified using an ÄKTA
Avant (GE Healthcare, USA). The biomass pellet was re-
suspended in 40ml Denaturation Solublisation Buffer
(DSB; 50mM NaH2PO4, 300mM NaCl, 8M urea; pH 7.9)
and incubated for 2 h at 37 °C with shaking at 50 rpm.
This was then lysed by sonication and centrifuged at 4080
g for 10min at 4 °C. The supernatant was clarified through
a 0.45 μm syringe filter and loaded onto a 25ml bed vol-
ume Ni-NTA (nickel-nitrilotriacetic acid) column on the
ÄKTA Avant, pre-equilibrated with DSB. After loading,
the column was washed with DSB, and HSK was refolded
on the column using a linear gradient from 100% DSB to
100% of the urea-free Lysis Equilibration Buffer (50mM
NaH2PO4, 300mM NaCl; pH 7.9) before being eluted off
the resin using Elution Buffer (50mM NaH2PO4, 300mM
NaCl, and 250mM Imidazole; pH 8.0). The eluate was dia-
lysed overnight in HSK’s selected dialysis buffer (Table 4),
and concentrated five-fold through a Vivaspin 10 kDa
MWCO column (Sartorius).
The concentration of the proteins was determined
using the Qubit® 2.0 Fluorometer (Life Technologies.
USA) and Qubit Protein Assay Kit, as recommended by
the manufacturer. A volume of 50 μl of all proteins ex-
cept AK and GK, were snap-frozen in liquid nitrogen
and stored at − 80 °C until assayed. For AK and GK, ali-
quots of 50 μl of the dialysed protein were mixed with
50% [v/v] glycerol before storage at − 80 °C.
Determination of enzyme activity
The kinase samples were thawed on ice prior to setting up
the enzyme assays. The HPLC assay reactions were carried
out in 100 μl volumes and incubated at 37 °C. The assay
was carried out as described by [10]. Briefly, the assay reac-
tions consisted of 90 μl of the prepared reaction mixture
(Table 5) with either 10 μl of enzyme, prepared in triplicate
or 10 μl distilled water, prepared in duplicate, which served
as a control blank. A range of ATP concentrations was
assayed, with ATP and MgCl2 concentrations always kept
at a 1:1 ratio [24]. After the pre-determined reaction time
(Table 5), the reactions were stopped with 5% [v/v] 200
mM EDTA.2Na.2H2O and subsequently loaded onto an
Agilent 1100 HPLC to measure the adenosine diphosphate
(ADP) product formation and the reduction of the ATP
substrate. The HPLC automatically injected 0.2 μl of each
sample reaction mix onto a Phenomenex 5 μ LUNA C18
column with the mobile phase containing PIC A® (Waters
Corporation. USA), 250ml acetonitrile and 7 g KH2PO4
per litre of water. The flow rate of the mobile phase was 1
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ml/min and the separated reactants were detected using a
UV detector to measure absorbance at a wavelength of
259 nm. AMP, ADP and ATP standards were used to cali-
brate the HPLC and the levels of ADP in each sample were
determined by using Agilent ChemStation (Revision
B.02.01) software (Agilent Technologies. USA). Absorb-
ance values obtained for the control containing distilled
water were subtracted from the enzyme reactions.
Favorable enzyme activity, in this study, was defined by
achieving linearity to demonstrate a constant rate, as well
as attaining percentage conversions (of ATP to ADP)
within the range of 5–15%.
Pelargonium sidoides inhibitory activity
The Mtb kinases were thawed on ice. A 100 mg/ml stock
solution of the P. sidoides crude extract was prepared in
Table 3 Forward and reverse primers used to amplify specific kinase genes. Note also preferred vector for each construct
Kinase Gene and Rv identifier Forward and Reverse
primers (5′→ 3′)
Restri-ction Enzyme
Recogni-tion site
(underli-ned)
Selected
pET vector
NDK ndkA Rv2445c ndkA-Fwd pET-16b
GGCATATGACCGAACGGACTCTGGTACTG NdeI
ndkA-Rev
GTGGATCCTTAGGCGCCGGGAAACCAG BamHI
HSK thrB Rv1296 thrB-Fwd pET-20a
GGCATATGGTGACTCAAGCATTG NdeI
thrB-Rev
GTCTCGAGACCGGGAACTCTTACTG XhoI
AK ackA
Rv0409
ackA-Fwd pET-16b
GGCATATGGAGTAGCACCGTGCTGGTGATCAA NdeI
ackA-Rev
GTGGATCCTTACGCTCGGCGTCCGCCCAG BamHI
GK glpK
Rv3696c
glpK-Fwd pET-16b
(GGCATATGTCCGACGCCATCCTAG NdeI
glpK-Rev
CATGTCGACTTAGGACACGTCAACCCAATCC SalI
ThiL thil
Rv2977c
thil-Fwd pET-28a
GGTACATATGACCACTAAAGATCACTC NdeI
thil-Rev
GATCTCGAGTTACCCTAGCGAACCTTG XhoI
RBKS rbks
Rv2436
rbks-Fwd pET-28a
GTACATATGGCAAACGCCAGTGAG NdeI
rbks-Rev
GATCTCGAGTTATGAACCGTTGTG XhoI
AsKa ask
Rv3709c
ask alpha-Fwd pCDF-
GATTACATATGGCGCTCGTCGTGCAG NdeI Duet-1
ask alpha-Rev (alpha)
GATGTCGACTTACCGTCCCGTCCCCG-3’ SalI
ask beta-Fwd pET-26a
GATCATATGGAAGACCCCATCCTGACCG NdeI (beta)
ask beta-Rev
GCCCCTGCCCTGCCCAGCTGTATG SalI
SK aroK
Rv2539c
Primers were not designed as the aroK plasmid was
received from the laboratory of Chris Abell, University
of Cambridge
pET-15b
a AsK consists of 2 hetero-monomers (alpha and beta), to be co-expressed
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distilled water. A 10-fold serial dilution of the aqueous
plant extracts, ranging from 1 × 101 mg/ml to 1 × 10− 5
mg/ml, was then prepared before being stored at −
20 °C. The inhibitory activity determination was carried
out using HPLC enzyme assays as described earlier, at a
single ATP and MgCl2 concentration (1 mM each), and
with the addition of varying concentrations of the P.
sidoides plant extract. A water-only control was run in
parallel, to serve as a negative control for activity com-
parison analysis. The reaction mixtures of each kinase
(Table 5) were incubated at 37 °C for a specific time and
thereafter stopped with 5% [v/v] 200mM EDTA.2-
Na.2H2O. The reactions were subsequently analysed as
above. All assays were carried out in triplicate and the
standard deviation determined and plotted as part of the
data. The IC50 values were calculated, with the aid of
GraphPad Prism 5 (GraphPad Software Inc. USA) as
specified by the software when plotting log [Inhibitor]
concentration versus the enzyme activity.
Enzyme acticvity assays contained 0.25–1.5mM ATP and
2mM MgCl2. Dose response assays contained 0–1mg/ml
P. sidoides plant extract, 1mM ATP and 1mMMgCl2.
Protein expression validation
Each purified protein was then proteolytically fragmen-
ted using the Thermo Scientific™ SMART Digest™ kit as
per the manufacturer’s instructions. The peptide frag-
ments were lyophilized and made up in 20 μl 2% v/v
acetonitrile containing 0.1% v/v formic acid for mass
spectroscopy analysis.
Liquid chromatography (Dionex nano-RSLC)
Liquid chromatography was performed on a Thermo Sci-
entific Ultimate 3000 RSLC equipped with a 5mm× 300
mm C18 trap column (Thermo Scientific) and a CSH 25
cm× 75 μm 1.7 μm particle size C18 column (Waters) ana-
lytical column. The solvent system employed was loading:
2% acetonitrile:water; 0.1% formic acid; Solvent A: 2%
acetonitrile:water; 0.1% formic acid and Solvent B: 100%
Table 4 Dialysis buffers used for each Mtb kinase
Kinase Dialysis buffer
NDK 50mM Tris pH 8.0
100 mM KCl
1 mM DTT
1mM MgCl2
HSK 50mM MOPS pH 8.0
150 mM NaCl
1 mM DTT
10mM MgCl2
AK and GK 50mM Tris pH 7.5
150 mM NaCl
1 mM DTT
5mM MgCl2
ThiL and RBKS 50mM MOPS pH 7.6
150 mM NaCl
1 mM DTT
10mM MgCl2
AsK 50mM Tris pH 6.0
200 mM NaCl
1 mM DTT
10mM MgCl2
SK 50mM Tris pH 7.5
1 M NaCl
Table 5 Details of assay reactions for determination of enzyme activity and inhibition assays in the presence of various dilutions of
P. sidoides extract
Enzyme Enzyme Activity Assay reaction mixtures P. sidoides inhibition Assay reaction mixtures Incubation time
NDK 100mM K-PO4 buffer (pH 6.8), 250 mM KCl
5 nM enzyme, 0.2 M Thymidine diphosphate
100 mM K-PO4 buffer (pH 6.8), 250 mM KCl
5 nM enzyme, 0.2 M Thymidine diphosphate
40 mins
HSK 50 mM HEPES buffer (pH 7.0), 450 mM KCl
704 nM enzyme, 10 mM Homoserine
50 mM HEPES buffer (pH 7.0), 450 mM KCl
704 nM enzyme, 10 mM Homoserine
4 h
AK 100mM Tris buffer (pH 7.0), 250 mM KCl
223 nM enzyme, 10 mM Na-acetate
100 mM Tris buffer (pH 7.0), 250 mM KCl
223 nM enzyme, 10 mM Na-acetate
24 h
GK 100mM Tris buffer (pH 7.0), 250 mM KCl
208.6 nM enzyme, 100 mM Glycerol
100 mM Tris buffer (pH 7.0), 250 mM KCl
208.6 nM enzyme, 100 mM Glycerol
24 h
ThiL 100 mM Tris buffer (pH 8.0), 250 mM KCl
2074 nM enzyme, 1 mM Thiamine monophosphate
100 mM Tris buffer (pH 8.0), 250 mM KCl
2074 nM enzyme, 1 mM Thiamine monophosphate
5 h
RBKS 100mM Tris buffer (pH 7.2), 100 mM KCl
250 nM enzyme, 10 mM D-ribose
100mM Tris buffer (pH 7.2), 100 mM KCl
250 nM enzyme, 10 mM D-ribose
4 h
AsK 100mM Tris-HCl buffer (pH 7.5), 178.2 nM enzyme
10 mM L-Aspartic acid
100 mM Tris-HCl buffer (pH 7.5), 178.2 nM enzyme
10 mM L-Aspartic acid
6 h
SK 100mM K-PO4 buffer (pH 6.8), 500 mM KCl
10 nM enzyme, 8 mM shikimic acid
100 mM K-PO4 buffer (pH 6.8), 500 mM KCl
10 nM enzyme, 8 mM shikimic acid
20 mins
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acetonitrile:water, 0.1% formic acid. The samples were
loaded onto the trap column using loading solvent at a
flow rate of 10 μL/min from a temperature controlled
autosampler set at 7 °C. Loading was performed for 5min
before the sample was eluted onto the analytical column.
Flow rate was set to 325 nL/minute and the gradient gen-
erated as follows: 2.0 -10% B for 4min; followed by 10–
35% B from 4 to 60min and finally 35–50% B from 60 to
70min. Chromatography was performed at 40 °C and the
outflow delivered to the mass spectrometer through a
stainless steel nano-bore emitter.
Mass spectrometry
Mass spectrometry was performed using a Thermo Sci-
entific Fusion mass spectrometer equipped with a
Nanospray Flex ionization source. The sample was intro-
duced through a stainless steel emitter. Data was col-
lected in positive mode with spray voltage set to 1.8 kV
and ion transfer capillary set to 280 °C. Spectra were in-
ternally calibrated using polysiloxane ions at m/z =
445.12003 and 371.10024. MS1 scans were performed
using the orbitrap detector set at 120000 resolution over
the scan range m/z = 350–1650 with Adaptive Gain Con-
trol (AGC) target at 5 × 104 and maximum injection
time of 40 ms. Data was acquired in profile mode.
MS2 acquisitions were performed using monoisotopic
precursor selection for ion with charges + 2 − + 7 with
error tolerance set to +/− 10 ppm. Precursor ions were
excluded from fragmentation once for a period of 60 s.
Precursor ions were selected for fragmentation in High
Energy Dissociation (HCD) mode using the quadrupole
mass analyser with HCD energy set to 30%. Fragment
ions were detected in the orbitrap mass analyzer set to
15,000 resolution. The AGC target was set to 5 × 104
and the maximum injection time to 30 ms. These data
was acquired in centroid mode.
The raw files generated by the mass spectrometer were
imported into Proteome Discoverer v1.4 (Thermo Scien-
tific) and processed using the Sequest algorithm. Data-
base interrogation was performed against a concatenated
database created using the Uniprot M. tuberculosis data-
base with the cRAP contaminant database. Semi-tryptic
cleavage with 2 missed cleavages was allowed for. Pre-
cursor mass tolerance was set to 10 ppm and fragment
mass tolerance set to 0.05 Da. Demamidation (arginine
and glutamine), oxidation (methionine) and acetylation
of protein N-terminal was allowed as dynamic modifica-
tions and thiomethyl of cysteine as static modification.
Peptide validation was performed using the Target-
Decoy PSM validator node. The output files from Prote-
ome Discoverer were imported in to Scaffold Q+ and
the assignments validated using X1Tandem and the Pep-
tideProphet and ProteinProphet algorithms.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12896-020-00643-w.
Additional file 1 SDS-PAGE gels of the Mtb his-tagged kinases purified
from E. coli BL21 (DE3). A) Nucleotide diphosphate kinase. B) Histidine kin-
ase. C) Acetate kinase and Glycerol kinase. D) Thiamine monophosphate
kianse (T) and Ribokinase (R). E) Aspartokinase. F) Skikimate kinase. Protein
concentrations of purified enzymes.
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